

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.weylo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/578,660	05/09/2006	Philip C. Dell'orco	PU60518	4972
20402 7550 0408/2010 GlaxoSmithKline GLOBAL PATENTS -US, UW2220			EXAMINER	
			AULAKH, CHARANJIT	
P. O. BOX 1539 KING OF PRUSSIA, PA 19406-0939			ART UNIT	PAPER NUMBER
			1625	
			NOTIFICATION DATE	DELIVERY MODE
			04/08/2010	EL ECTRONIC

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

US\_cipkop@gsk.com

## Response to Rule 312 Communication

Application No.	Applicant(s)	
10/578.660	DELL'ORCO ET AL.	
Examiner	Art Unit	
Charanjit S. Aulakh	1625	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

1. 🛛 The	amendment filed on 17 March 2010 under 37 CFR 1.312 has been considered, and has been:
a) 🔲	entered.
b) 🛛	entered as directed to matters of form not affecting the scope of the invention.
c) 🗆	disapproved because the amendment was filed after the payment of the issue fee.  Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.
d) 🔲	disapproved. See explanation below.
e) 🔲	entered in part. See explanation below.
	(Charaniit S Aulakh)

Primary Examiner, Art Unit 1625